Studi scientifici principali
- Scheda tecnica Sovaldi (riferimenti su tutti i paragrafi del documento)
- Indicazioni terapeutiche approvate da EMA
- Eric Lawitz,1 Fred F. Poordad et al, APASL 2014
- Michael P. Curry, Xavier Forns et al, AASLD 2013
- Didier Samuel, Michael Charlton, Edward Gane et al. EASL 2104
Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter Study - Nezam Afdhal, Gregory Everson, Jose Luis Calleja et al, EASL 2014
Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety - Mark S Sulkowski, Ira M Jacobson, Reem Ghalib,et al., EASL 2014
Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis - Eric Lawitz, Reem Ghalib, Maribel Rodriguez-Torres, et al, EASL 2014
Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder/treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2)
